SANUWAVE Health (OTCMKTS: SNWV) and Teleflex (NYSE: TFX) Financial Contrast

SANUWAVE Health (OTCMKTS: SNWVGet a rating) and Teleflex (NYSE: TFXGet a rating) are two medical companies, but which company is better? We’ll compare the two companies based on valuation strength, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Notes

This is a summary of the current ratings of SANUWAVE Health and Teleflex, as reported by MarketBeat.

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
SANUWAVE Health 0 0 0 0 N / A
Teleflex 0 5 7 0 2.58

Teleflex has a consensus price target of $389.75, indicating a potential upside of 46.24%. Given Teleflex’s likely higher upside, analysts clearly believe that Teleflex is more favorable than SANUWAVE Health.

Insider and Institutional Ownership

12.9% of SANUWAVE Health shares are held by institutional investors. Comparatively, 92.2% of Teleflex shares are held by institutional investors. 9.7% of SANUWAVE Health shares are held by company insiders. By comparison, 1.3% of Teleflex shares are held by insiders of the company. Strong institutional ownership indicates that hedge funds, endowments, and large fund managers believe a company is poised for long-term growth.

Valuation and benefits

This table compares the gross revenue, earnings per share (EPS), and valuation of SANUWAVE Health and Teleflex.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
SANUWAVE Health $4.06 million 10.19 -$30.94 million N / A N / A
Teleflex $2.81 billion 4.45 $485.37 million $10.29 25.90

Teleflex has higher revenue and profit than SANUWAVE Health.


This table compares the net margins, return on equity and return on assets of SANUWAVE Health and Teleflex.

Net margins Return on equity return on assets
SANUWAVE Health -262.90% N / A -143.35%
Teleflex 17.31% 17.24% 9.08%

Volatility and risk

SANUWAVE Health has a beta of 0.46, which means its price is 54% less volatile than the S&P 500. In comparison, Teleflex has a beta of 1.13, which means its price is 13% more volatile than the S&P 500.


Teleflex beats SANUWAVE Health on 9 out of 11 factors compared between the two stocks.

Company Profile SANUWAVE Health (Get a rating)

SANUWAVE Health, Inc., a shockwave technology company, researches, develops, and markets noninvasive, high-energy, and acoustic shockwaves for regenerative medicine and other applications in the United States and around the world. Its shock waves are used to produce a biological response resulting in the healing of the body through the repair and regeneration of musculoskeletal and vascular tissues and structures. The Company’s primary regenerative product is the dermaPACE device for the treatment of diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biological signaling and angiogenic responses, including new vasculature and improved microcirculation, which helps restore the body’s normal healing and regenerative processes. The Company is also focused on applying its pulsed acoustic cell expression technology in the areas of wound healing, orthopedics, plastics/cosmetics and heart. Additionally, it offers UltraMIST, a non-contact, non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries and surgical wounds; and the orthoPACE system to treat tendinopathies and acute, unhealed fractures. The company was founded in 2005 and is based in Suwanee, Georgia.

Teleflex Company Profile (Get a rating)

Teleflex logoTeleflex Incorporated designs, develops, manufactures and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that include Arrow-branded catheters, catheter tip navigation and positioning systems, and intraosseous access systems for delivery of intravenous therapies, pressure measurement artery and collection of blood samples via a single puncture site. The Company also offers interventional products, which include various coronary catheters, structural cardiac therapies, and peripheral interventional and cardiac assist products used by interventional cardiologists and radiologists and vascular surgeons; and Arrow brand catheters, Guideline and Trapliner catheters, Manta Vascular Closure devices and Arrow Oncontrol. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine and military channels; and surgical products, including metal and polymer ligation clips and surgical fascial closure systems used in laparoscopic surgical procedures, percutaneous surgical systems and other surgical instruments. The company also offers interventional urology products including the UroLift System, an invasive technology for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry and ventilation management products for use in a variety of care settings. It provides urology products, such as catheters, urine collectors, catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Get news and reviews for SANUWAVE Health Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for SANUWAVE Health and related companies with’s free daily email newsletter.

About John Tuttle

Check Also

New FDA draft guidelines aim to protect children participating in clinical trials

SILVER SPRING, MD., September 23, 2022 /PRNewswire/ — Today, the United States Food and Drug …